


Catalog # 10-2181

VX-702

CAS# 745833-23-2

6-[(Aminocarbonyl)(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)-3-pyridinecarboxamide

Lot # X106735



A potent and selective inhibitor of p38 MAP kinases, p38 α MAPK and p38 β (K_D = 3.7 and 17 nM respectively).¹ Inhibits IL-6, IL-1 β and TNF α production in LPS-primed blood.¹ Inhibits p38 in platelets stimulated by thrombin, collagen or thromboxane agonist U-46619 at 1 μ M.² Provides only modest clinical efficacy in rheumatoid arthritis.^{3,4} Delays platelet lesions and leads to better maintenance of stored platelets.⁵

- 1) Goldstein *et al.* (2010), *Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders*; J. Med. Chem., **53** 2345
- 2) Kuliopulos *et al.* (2004), *Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation*; Thromb. Haemostasis, **92** 1387
- 3) Damianov *et al.* (2009), *Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies*; Arthrit. Rheumat., **60** 1232
- 4) Ding *et al.* (2006), *Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome*; Curr. Opin. Investig. Drugs, **7** 1020
- 5) Scripchenko *et al.* (2013), *An inhibition of p38 mitogen activated protein kinase delays the platelet storage lesion*; PLoS One, **8(8)**e 70732

PHYSICAL DATA

Molecular Weight:	404.32
Molecular Formula:	C ₁₉ H ₁₂ F ₄ N ₄ O ₂
Purity:	98% by HPLC
	NMR: (Conforms)
Solubility:	DMSO (up to 40 mg/ml) or Ethanol (up to 2 mg/ml)
Physical Description:	White solid
Storage and Stability:	Store as supplied desiccated at -20°C for up to 2 years from the date of purchase. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.